Does the FDA’s ‘breakthrough’ drug program need to be reformed? Harvard skeptics say yes

Of all the expedited review programs that the FDA has set up, none are as popular as the “breakthrough” therapy designation. And a group of high-profile skeptics says that has created some problems that need to be addressed.